Hydrogen Therapy in Patients With Moderate Covid-19
Status:
Not yet recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
SARS-CoV-2 is the agent responsible for a new infectious respiratory disease called Covid-19
(for CoronaVirus Disease 2019) which is mainly characterized by potentially severe and fatal
lung damage. The severity of the clinical signs associated with this pathology requires the
admission to hospital of approximately 20% of patients, 5%-10% of whom will be admitted to
intensive care. The most severe cases of this pathology begin with dyspnea which worsens
rapidly around the 7th-10th day of the disease into an acute respiratory distress syndrome
(ARDS) which requires the patient to be put under mechanical ventilation in the intensive
care unit and is responsible for the majority of deaths. Certain biological parameters
suggest a massive and brutal release of cytokines (interleukins IL-6, IL-8 and IL-10 mainly)
secondary to a syndrome of macrophagic activation mainly in the pulmonary level. Several
therapeutic trials aimed at reducing or controlling this immune storm are in progress (anti
IL-6 antibodies, anti r IL6 Ab, corticosteroids). Molecular hydrogen acts on the final path
of this complex inflammatory cascade by inhibiting the cellular action of reactive oxygen
species. Its early use combined with nasal oxygen therapy could prevent this worsening of the
respiratory system, so could be likely to limit the risk of overflow of intensive care
services during the pandemic and save lives. The aim of this study is to evaluate the safety
and the Dose Limiting Toxicity (DLT) of hydrogen therapy delivered by a nasal cannula in
addition to conventional oxygen therapy in patients with moderate Covid-19